VanEck Biotech ETF Price & Performance (BBH)

Assetmark Inc. has significantly reduced its position in the VanEck Biotech ETF by 88.9% during the fourth quarter. The institutional investor now holds 384 shares, valued at $60,000, down from 3,081 shares. This move reflects broader shifts among institutional investors in the biotech ETF space.12

The VanEck Biotech ETF experienced a dramatic 427.3% increase in short interest in February, reaching 11,600 shares. This sharp rise in short positions suggests growing bearish sentiment or hedging activity among investors in the biotech sector.23

Jones Financial Companies reduced its stake in the VanEck Biotech ETF by 4% during Q4, now holding 2,617 shares worth $411,000. This minor adjustment aligns with broader trends of fluctuating institutional investments in the biotech-focused ETF.34